Skip to main
AXGN
AXGN logo

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Axogen Inc. is positioned for significant growth due to strong market dynamics stemming from enhanced head and neck cancer treatment outcomes, which have increased patient survival rates and subsequently demand for iatrogenic nerve repair solutions. The company forecasts that high potential accounts will contribute 66% to revenue growth across 780 accounts, with an expected 21% uplift in average productivity per account, indicating effective market penetration and product adoption. Additionally, improvements in gross margins driven by enhanced operational efficiencies and a substantial 70% increase in research publications since 2019 suggest a strengthening foundation for future growth in the peripheral nerve repair sector.

Bears say

Axogen Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to low awareness of its products among key surgical specialists, which hampers market adoption. The company's prospects are further threatened by reliance on autograft procedures, as surgeons may prefer familiar methods over trying Axogen's innovative offerings. Additionally, ongoing issues with regulatory approvals and potential financing needs for profitability raise serious concerns regarding Axogen's ability to sustain growth and market penetration in a competitive environment.

AxoGen (AXGN) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 15 analysts, AxoGen (AXGN) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.